tiprankstipranks
In this article:
Blurbs

Analysts’ Top Healthcare Picks: Corcept Therapeutics (CORT), Stealth Biotherapeutics (MITO)

In this article:
In this article:

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Corcept Therapeutics (CORTResearch Report), Stealth Biotherapeutics (MITOResearch Report) and Cerevel Therapeutics Holdings (CEREResearch Report) with bullish sentiments.

Corcept Therapeutics (CORT)

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Corcept Therapeutics today and set a price target of $29.00. The company’s shares closed last Tuesday at $20.31.

According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of 10.5% and a 38.9% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Janux Therapeutics Inc, Cellectar Biosciences, and Harpoon Therapeutics.

Corcept Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $29.67, implying a 50.8% upside from current levels. In a report issued on February 2, Canaccord Genuity also initiated coverage with a Buy rating on the stock with a $30.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Stealth Biotherapeutics (MITO)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Stealth Biotherapeutics today and set a price target of $4.00. The company’s shares closed last Tuesday at $0.65, close to its 52-week low of $0.61.

According to TipRanks.com, Chen is a 5-star analyst with an average return of 15.8% and a 36.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as Ortho Clinical Diagnostics Holdings, Interpace Diagnostics Group, and HTG Molecular Diagnostics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Stealth Biotherapeutics with a $4.00 average price target.

Cerevel Therapeutics Holdings (CERE)

H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Cerevel Therapeutics Holdings today and set a price target of $50.00. The company’s shares closed last Tuesday at $30.10.

According to TipRanks.com, Tsao is a 3-star analyst with an average return of 3.0% and a 39.0% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Praxis Precision Medicines, and Protagonist Therapeutics.

Currently, the analyst consensus on Cerevel Therapeutics Holdings is a Strong Buy with an average price target of $42.33, implying a 40.7% upside from current levels. In a report released yesterday, Stifel Nicolaus also reiterated a Buy rating on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CORT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed